Olaparib interactions
Full monograph for OlaparibCheck it against another medicine
Medicines
294 documented
Mechanism
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Adalimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Apalutamide | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Aprepitant | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Armodafinil | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Baricitinib | Major | Synergy | Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies… | 4 sources — open the full entry |
| Bosentan Monohydrate | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Calcium Dobesilate + Lidocaine + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily…2 documented mechanisms | 17 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Cenobamate | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Ceritinib | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| CiprofloxacinbaseOphthalmic | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Ciprofloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily…2 documented mechanisms | 13 sources — open the full entry |
| Ciprofloxacin + Hydrocortisone Acetate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Clozapine | Major | Synergy | Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. | 9 sources — open the full entry |
| Crizotinib | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Deferiprone | Major | Synergy | Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity… | 5 sources — open the full entry |
| Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Dexamethasone + Chloramphenicol | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily…2 documented mechanisms | 12 sources — open the full entry |
| Dexamethasone + Levofloxacin | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Dexamethasone + Neomycin + Glacial Acetic Acid | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Dexamethasone + Neomycin Sulphate + Polymyxin B Sulphate | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Dexamethasone + Tobramycin | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Diltiazem Hydrochloride | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Efavirenz | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| ErythromycinLotionOral | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Etanercept | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Gatifloxacin + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Golimumab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Coadministration with moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 6 sources — open the full entry |
| Infliximab | Major | Synergy | The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections… | 6 sources — open the full entry |
| Itraconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Ketoconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Lamivudine + Zidovudine + Nevirapine | Major | Metabolism · Synergy | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily…2 documented mechanisms | 11 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Leflunomide | Major | Synergy | The use of leflunomide with other immunosuppressive or myelosuppressive agents may increase the risk of infections. The risk is thought to extend to… | 2 sources — open the full entry |
| Lopinavir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Lorlatinib | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Moxifloxacin Hydrochloride + Dexamethasone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Nelfinavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Phenobarbital | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
| Posaconazole | Major | Metabolism | Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of olaparib, which is primarily metabolized by the… | 9 sources — open the full entry |
| Primidone | Major | Metabolism | Coadministration with potent and moderate inducers of CYP450 3A4 may significantly decrease the plasma concentrations of olaparib, which is primarily… | 7 sources — open the full entry |
Food & lifestyle
grapefruit juice
MajorMetabolism
Grapefruit juice may significantly increase the plasma concentrations of olaparib. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit.
What to do: Patients treated with olaparib should avoid consumption of grapefruit, grapefruit juice, starfruit (carambola), and Seville oranges.
3 sources
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Conditions
Conditions in which Olaparib needs care, as documented in this source.
Hepatic Insufficiency
ModerateOlaparib primarily undergoes hepatic metabolism via CYP450 3A4 and CYP450 3A5; the majority of metabolism is through oxidation with some metabolites undergoing subsequent glucuronide or sulfate conjugation. No dose adjustment is needed in patients with mild hepatic impairment. It is recommended to use caution when using olaparib in patients with moderate or severe hepatic impairment as there are no data available. Close monitoring is recommended.
1 source
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Kidney Diseases
ModerateIn a olaparib renal impairment trial, the mean AUC increased by 24%, and the Cmax increased by 15%, in patients with mild renal impairment. In patients with moderate renal impairment, the AUC increased by 44% and the Cmax by 26%. No dose adjustment is needed in patients with mild renal impairment. The dose of olaparib in patients with moderate renal impairment should be adjusted according to the prescribing information. It is recommended to monitor for toxicity all patient with renal impairment. The pharmacokinetics of olaparib have not been evaluated in patients with severe renal impairment or end-stage renal disease.
1 source
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Neutropenia
ModerateOlaparib might cause Myelodysplastic Syndrome/Acute Myeloid Leukemia (MDS/AML), sometimes with fatal outcomes. Care should be exercised when using olaparib in patients with a history of previous cancer or bone marrow dysplasia. Do not start olaparib until patients have recovered from hematological toxicity caused by previous chemotherapy (<= Grade 1). It is recommended to monitor patients for hematological toxicities at baseline and monthly thereafter for clinically significant changes during treatment. Interrupt olaparib for prolonged hematological toxicities and monitor blood counts weekly until recovery and discontinue treatment if MDS/AML is confirmed.
1 source
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):
Respiration Disorders
ModeratePneumonitis, including fatal cases, occurred in <1% of patients treated with olaparib. It is recommended to interrupt treatment if patients present new or worsening respiratory symptoms such as dyspnea, cough and fever, or a radiological abnormality. Assess for the source of symptoms and if pneumonitis is confirmed, olaparib should be discontinued and the patient treated appropriately.
1 source
- "Product Information. Lynparza (olaparib)." Astra-Zeneca Pharmaceuticals (2014):